NCT06209177: A trial that was reported late by Arrowhead Pharmaceuticals
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06209177 |
|---|---|
| Title | A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ARO-CFB in Adult Healthy Volunteers and Adult Patients With Complement-Mediated Kidney Disease |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 5, 2024 |
| Completion date | March 31, 2025 |
| Required reporting date | March 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 24, 2026 |
| Days late | None |